A prospective observational cohort study evaluating European Respiratory Society guidelines found that combining whole-exome sequencing with quantitative telomere length assessment identified pathogenic variants or clinically relevant telomere shortening in patients with interstitial lung disease. The investigation, published in BMC Pulmonary Medicine, demonstrated that clinical selection criteria established by the European Respiratory Society effectively identify individuals who derive diagnostic benefit from specialized genetic and molecular evaluations.
The European Respiratory Society currently recommends formal genetic evaluation for carefully selected subsets of individuals presenting with interstitial lung disease. Despite the formal release of these clinical guidelines, prospective data assessing their actual diagnostic performance, clinical utility, and variant detection yield in routine clinical practice had remained limited, prompting the researchers to systematically evaluate the diagnostic strategy in a prospective patient cohort.
To rigorously examine the performance of these clinical criteria, the study enrolled 52 consecutive patients diagnosed with interstitial lung disease who met at least one European Respiratory Society indication for genetic evaluation. Each enrolled participant underwent dual diagnostic testing comprising comprehensive whole-exome sequencing alongside quantitative polymerase chain reaction assays to determine relative telomere length. By analyzing both molecular datasets in parallel, the investigative team evaluated the diagnostic yield across distinct clinical indications and determined how telomere length measurements complemented standard next-generation sequencing.
Whole-exome sequencing successfully identified pathogenic or likely pathogenic genetic variants in 4 of the 52 evaluated patients, representing an overall diagnostic yield of 7.7 percent. When categorized according to the primary clinical indication for referral, the diagnostic yield varied substantially across patient subgroups. The highest yield of causative genetic variants was observed among individuals evaluated for clinical suspicion of telomere biology disorders. In contrast, the researchers identified no pathogenic or likely pathogenic variants among patients referred solely for isolated early-onset interstitial lung disease who lacked any relative carrying a known disease-causing genetic variant.
Quantitative polymerase chain reaction testing for telomere length provided crucial diagnostic findings that extended beyond the sequencing results. The molecular assay detected short telomeres, defined as a length falling below the tenth percentile, in 21.2 percent of the overall cohort, representing 11 of the 52 evaluated patients. Importantly, these abnormally short telomeres were identified in patients who harbored no identifiable pathogenic variants on whole-exome sequencing, demonstrating that quantitative telomere analysis captured clinically meaningful biological abnormalities that sequencing alone failed to uncover.
The study authors concluded that their findings substantiate the clinical utility of current European Respiratory Society recommendations for directing genetic evaluation in interstitial lung disease. Patients presenting with familial interstitial lung disease and those with clinical indicators of telomere biology disorders appear to derive the greatest diagnostic advantage from testing. Furthermore, the researchers emphasized that conducting concurrent assessments using whole-exome sequencing and quantitative telomere length measurement delivers complementary clinical insight, potentially refining the diagnostic precision and long-term clinical management of inherited interstitial lung disease.
Subject of Research: Diagnostic utility of combined exome sequencing and telomere testing in interstitial lung disease
Article Title: Clinical utility of the ERS recommendations for genetic evaluation in interstitial lung disease: a prospective cohort study
Article References: Martina, S., Eva, P., Hana, S., Jan, B., Marie, D., Malgorzata, L., Andrea, H., & Milan, M. (2026). Clinical utility of the ERS recommendations for genetic evaluation in interstitial lung disease: a prospective cohort study. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-026-04849-0
Image Credits: AI Generated
DOI: 10.1186/s12890-026-04849-0
Keywords: interstitial lung disease, European Respiratory Society, whole-exome sequencing, telomere length measurement, telomere biology disorders, quantitative PCR, pathogenic variants, familial interstitial lung disease, early-onset lung disease, diagnostic yield, prospective cohort study, inherited lung disease, short telomeres, genetic evaluation, clinical utility, BMC Pulmonary Medicine
News Source: Barbara Leach. (November 12, 2026). Telomere and Exome Testing Identify Inherited Risks in Interstitial Lung Disease. Scienmag.



